Phase i study clinical trials phase ii as topic. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy2

Bone Marrow Monocytes, Activated Killer

Organisms2

Coxiella Glycyrrhiza uralensis

Diseases59

Neoplasms Neutropenia Thrombocytopenia Nausea Lung Neoplasms Leukopenia Vomiting Neoplasm Metastasis Hematologic Diseases Fatigue Neoplasm Recurrence, Local Stomatitis Carcinoma, Non-Small-Cell Lung Breast Neoplasms Disease Progression Diarrhea Melanoma Asthenia Drug-Related Side Effects and Adverse Reactions Colorectal Neoplasms Brain Stem Neoplasms Ovarian Neoplasms Recurrence Brain Neoplasms Peritoneal Neoplasms Agranulocytosis Head and Neck Neoplasms Kidney Neoplasms Carcinoma, Renal Cell Anorexia Alopecia Glioma Sarcoma Pancreatic Neoplasms Fever Carcinoma, Small Cell Lymphoma, Non-Hodgkin Adenocarcinoma Liver Neoplasms Prostatic Neoplasms Carcinoma Stomach Neoplasms Fallopian Tube Neoplasms Anemia Gastrointestinal Neoplasms Carcinoma, Squamous Cell Headache Exanthema Glioblastoma Mesothelioma Gastrointestinal Diseases Leukemia, Myeloid, Acute Neoplasms, Glandular and Epithelial Acute Disease Leukemia Mucositis Leukemia, Lymphocytic, Chronic, B-Cell Foot Dermatoses Nervous System Diseases

Chemicals and Drugs99

Antineoplastic Agents Paclitaxel Deoxycytidine Camptothecin Taxoids Antineoplastic Agents, Phytogenic Cisplatin Fluorouracil Organoplatinum Compounds Carboplatin Antibodies, Monoclonal, Humanized Antimetabolites, Antineoplastic Antibodies, Monoclonal Topotecan Quinazolines Dacarbazine Tegafur Oxonic Acid Doxorubicin Menogaril Leucovorin Angiogenesis Inhibitors Phenylurea Compounds Placebos Etoposide Nogalamycin Vinblastine Benzenesulfonates Ifosfamide Drug Combinations Protein Kinase Inhibitors Niacinamide Pyridines Granulocyte Colony-Stimulating Factor Cyclophosphamide Epothilones Antineoplastic Agents, Alkylating Prodrugs Topoisomerase I Inhibitors Recombinant Proteins Pyrroles Indoles Pyrazines Cancer Vaccines Thiophenes Acenaphthenes Antibiotics, Antineoplastic Bryostatins Pyrimidines Boronic Acids Mesna Sulfonamides Epirubicin Arabinonucleosides Mitoxantrone Sirolimus Immunotoxins Radiation-Sensitizing Agents Thalidomide Depsipeptides Hydroxamic Acids Quinolines Guanine Piperidines Uracil Dianhydrogalactitol Antibodies, Monoclonal, Murine-Derived Drugs, Investigational Aminopterin Benzamides Yttrium Radioisotopes Nitrogen Mustard Compounds Benzoquinones Tumor Markers, Biological Phthalazines Capsules Enzyme Inhibitors Thiosemicarbazones Farnesyltranstransferase Ricin Mitomycin Vincristine Maytansine Piperazines Lactones Liposomes Immunoconjugates Tubulin Modulators Glutamates Lactams, Macrocyclic Sialic Acid Binding Ig-like Lectin 2 Platinum Indazoles Receptor, Epidermal Growth Factor Interleukin-2 Triazines Pyrazoles Organophosphorus Compounds Trifluridine

Analytical, Diagnostic and Therapeutic Techniques and Equipment67

Clinical Trials as Topic Clinical Trials, Phase I as Topic Maximum Tolerated Dose Drug Administration Schedule Clinical Trials, Phase II as Topic Drug Evaluation Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Infusions, Intravenous Administration, Oral Area Under Curve Clinical Trials, Phase III as Topic Combined Modality Therapy Research Design Double-Blind Method Disease-Free Survival Survival Analysis Neoplasm Staging Feasibility Studies Metabolic Clearance Rate Survival Rate Patient Selection Follow-Up Studies Randomized Controlled Trials as Topic Controlled Clinical Trials as Topic Injections, Intravenous Placebos Salvage Therapy Remission Induction Prospective Studies Multicenter Studies as Topic Drug Therapy, Combination Pilot Projects Injections, Subcutaneous Cohort Studies Infusions, Parenteral Kaplan-Meier Estimate Endpoint Determination Clinical Protocols Radioimmunotherapy Prognosis Immunotherapy Treatment Failure Dose Fractionation Single-Blind Method Clinical Trials, Phase IV as Topic Sample Size Cross-Over Studies Infusions, Intra-Arterial Genetic Therapy Severity of Illness Index Risk Assessment Early Termination of Clinical Trials Infusion Pumps Radiotherapy Dosage Blood Cell Count Chemoradiotherapy Injections, Intralesional Drug Evaluation, Preclinical Immunotherapy, Active Chemotherapy, Adjuvant Questionnaires Platelet Count Reproducibility of Results Radiotherapy Radiotherapy, Adjuvant Risk Factors

Phenomena and Processes15

Maximum Tolerated Dose Dose-Response Relationship, Drug Area Under Curve Metabolic Detoxication, Phase II Time Factors Metabolic Clearance Rate Half-Life Drug Resistance, Neoplasm Metabolic Detoxication, Phase I Tissue Distribution Biological Availability Blood Cell Count Drug Interactions Food-Drug Interactions Platelet Count

Disciplines and Occupations5

Research Design Evidence-Based Medicine Medical Oncology Biomedical Research Outcome Assessment (Health Care)

Anthropology, Education, Sociology and Social Phenomena1

Quality of Life

Technology, Industry, Agriculture1

Humanities1

Quality of Life

Information Science3

Survival Rate Periodicals as Topic Questionnaires

Named Groups2

Healthy Volunteers Research Subjects

Health Care37

Clinical Trials as Topic Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Treatment Outcome Area Under Curve Clinical Trials, Phase III as Topic Double-Blind Method Disease-Free Survival Survival Analysis Feasibility Studies Survival Rate Patient Selection Follow-Up Studies Randomized Controlled Trials as Topic Controlled Clinical Trials as Topic Safety Prospective Studies Multicenter Studies as Topic Pilot Projects Cohort Studies Kaplan-Meier Estimate Clinical Protocols Treatment Failure Single-Blind Method Clinical Trials, Phase IV as Topic Clinical Trials Data Monitoring Committees Sample Size Cross-Over Studies Severity of Illness Index Risk Assessment Early Termination of Clinical Trials Congresses as Topic Guidelines as Topic Questionnaires Reproducibility of Results Risk Factors Outcome Assessment (Health Care)

Geographicals1

Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Humanities Information Science Named Groups Health Care Geographicals

Clinical Trials as Topic Clinical Trials, Phase I as Topic Maximum Tolerated Dose Drug Administration Schedule Neoplasms Clinical Trials, Phase II as Topic Drug Evaluation Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Infusions, Intravenous Dose-Response Relationship, Drug Antineoplastic Agents Paclitaxel Neutropenia Administration, Oral Area Under Curve Deoxycytidine Camptothecin Clinical Trials, Phase III as Topic Taxoids Thrombocytopenia Antineoplastic Agents, Phytogenic Nausea Cisplatin Combined Modality Therapy Fluorouracil Research Design Lung Neoplasms Organoplatinum Compounds Double-Blind Method Metabolic Detoxication, Phase II Carboplatin Time Factors Leukopenia Antibodies, Monoclonal, Humanized Disease-Free Survival Survival Analysis Vomiting Antimetabolites, Antineoplastic Neoplasm Metastasis Hematologic Diseases Antibodies, Monoclonal Topotecan Quinazolines Neoplasm Staging Feasibility Studies Fatigue Metabolic Clearance Rate Neoplasm Recurrence, Local Survival Rate Dacarbazine Stomatitis Patient Selection Tegafur Carcinoma, Non-Small-Cell Lung Oxonic Acid Doxorubicin Follow-Up Studies Menogaril Randomized Controlled Trials as Topic Leucovorin Controlled Clinical Trials as Topic Injections, Intravenous Breast Neoplasms Disease Progression Half-Life Angiogenesis Inhibitors Phenylurea Compounds Diarrhea Placebos Safety Etoposide Melanoma Asthenia Salvage Therapy Drug-Related Side Effects and Adverse Reactions Nogalamycin Vinblastine Remission Induction Benzenesulfonates Colorectal Neoplasms Ifosfamide Brain Stem Neoplasms Ovarian Neoplasms Drug Combinations Coxiella Prospective Studies Recurrence Protein Kinase Inhibitors Niacinamide Pyridines Granulocyte Colony-Stimulating Factor Cyclophosphamide Multicenter Studies as Topic Epothilones Brain Neoplasms Antineoplastic Agents, Alkylating Drug Resistance, Neoplasm Prodrugs Drug Therapy, Combination

No FAQ available that match "phase i study clinical trials phase ii as topic"